<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">86189</article-id><article-id pub-id-type="doi">10.7554/eLife.86189</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>Death by a thousand cuts through kinase inhibitor combinations that maximize selectivity and enable rational multitargeting</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-303580"><name><surname>Outhwaite</surname><given-names>Ian R</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2037-3261</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-112602"><name><surname>Singh</surname><given-names>Sukrit</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1914-4955</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-307755"><name><surname>Berger</surname><given-names>Benedict-Tilman</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-45919"><name><surname>Knapp</surname><given-names>Stefan</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5995-6494</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-16065"><name><surname>Chodera</surname><given-names>John D</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0542-119X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-15712"><name><surname>Seeliger</surname><given-names>Markus A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0990-1756</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Pharmacological Sciences</institution>, <institution>Stony Brook University</institution>, <addr-line><named-content content-type="city">Stony Brook</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Computational and Systems Biology Program</institution>, <institution>Memorial Sloan Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Institute of Pharmaceutical Chemistry</institution>, <institution>Goethe University Frankfurt</institution>, <addr-line><named-content content-type="city">Frankfurt</named-content></addr-line>, <country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-217314"><name><surname>Yang</surname><given-names>Yongliang</given-names></name><role>Reviewing editor</role><aff><institution>Dalian University of Technology</institution>, <country>China</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>markus.seeliger@stonybrook.edu</email> (MS);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>04</day><month>12</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e86189</elocation-id><history><date date-type="received"><day>14</day><month>01</month><year>2023</year></date><date date-type="accepted"><day>03</day><month>12</month><year>2023</year></date></history><permissions><copyright-statement>Â© 2023, Outhwaite et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Outhwaite et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-86189-v1.pdf"/><abstract><p>Kinase inhibitors are successful therapeutics in the treatment of cancers and autoimmune diseases and are useful tools in biomedical research. However, the high sequence and structural conservation of the catalytic kinase domain complicates the development of selective kinase inhibitors. Inhibition of off-target kinases makes it difficult to study the mechanism of inhibitors in biological systems. Current efforts focus on the development of inhibitors with improved selectivity. Here, we present an alternative solution to this problem by combining inhibitors with divergent off-target effects. We develop a multicompound-multitarget scoring (MMS) method that combines inhibitors to maximize target inhibition and to minimize off-target inhibition. Additionally, this framework enables optimization of inhibitor combinations for multiple on-targets. Using MMS with published kinase inhibitor datasets we determine potent inhibitor combinations for target kinases with better selectivity than the most selective single inhibitor and validate the predicted effect and selectivity of inhibitor combinations using <italic>in vitro</italic> and <italic>in cellulo</italic> techniques. MMS greatly enhances selectivity in rational multitargeting applications. The MMS framework is generalizable to other non-kinase biological targets where compound selectivity is a challenge and diverse compound libraries are available.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>None</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R35GM119437</award-id><principal-award-recipient><name><surname>Seeliger</surname><given-names>Markus A</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32GM136572</award-id><principal-award-recipient><name><surname>Outhwaite</surname><given-names>Ian R</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01GM121505</award-id><principal-award-recipient><name><surname>Chodera</surname><given-names>John D</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001021</institution-id><institution>Damon Runyon Cancer Research Foundation</institution></institution-wrap></funding-source><award-id>DRQ-14-22</award-id><principal-award-recipient><name><surname>Singh</surname><given-names>Sukrit</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32GM008444</award-id><principal-award-recipient><name><surname>Outhwaite</surname><given-names>Ian R</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100023921</institution-id><institution>Structural Genomics Consortium</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Knapp</surname><given-names>Stefan</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution>German Translational Cancer Network</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Knapp</surname><given-names>Stefan</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>1399</award-id><principal-award-recipient><name><surname>Berger</surname><given-names>Benedict-Tilman</given-names></name><name><surname>Knapp</surname><given-names>Stefan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Benedict-Tilman Berger, is the CEO and a shareholder of CELLinib GmbH, Frankfurt, Germany..</p></fn><fn fn-type="conflict" id="conf3"><p>John D Chodera, is a current member of the Scientific Advisory Boards of OpenEye Scientific Software, Interline Therapeutics, and Redesign Science. The Chodera laboratory receives or has received funding from the National Institute of Health, the National Science Foundation, the Parker Institute for Cancer Immunotherapy, Relay Therapeutics, Entasis Therapeutics, Silicon Therapeutics, EMD Serono (Merck KGaA), AstraZeneca, Vir Biotechnology, XtalPi, Interline Therapeutics, and the Molecular Sciences Software Institute, the Starr Cancer Consortium, the Open Force Field Consortium, Cycle for Survival, a Louis V. Gerstner Young Investigator Award, and the Sloan Kettering Institute. A complete funding history for the Chodera lab can be found at http://choderalab.org/funding..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Instructions to run MMS, code, datasets, and MMS results are available at: https://github.com/iouthwaite/inhibitor_combinations</p></sec><supplementary-material><ext-link xlink:href="elife-86189-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>